

PCR-/NAT *Helicobacter pylori* (RV 533) Mai 2026



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

Proben Nr.	Erwartet / expected	Probenzusammensetzung / Sample composition
533 260519 01	++	61/ 71 <i>Helicobacter pylori</i> (~ 1x10 ⁵ CFU/mL) Clarithromycin resistant (AG mut., A2143G (23S rDNA))
533 260519 02	Ø	62 <i>Escherichia coli</i> K12
533 260519 03	+	61/ 71 <i>Helicobacter pylori</i> (~ 1x10 ⁴ CFU/mL) Clarithromycin resistant (AG mut., A2143G (23S rDNA))
533 260519 04	+++	61/ 71 <i>Helicobacter pylori</i> (~ 1x10 ⁶ CFU/mL) Clarithromycin resistant (AG mut., A2143G (23S rDNA))

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

n = 53	Proben Nr. (Sample no.)				Inhibition				
Befund Result	01	02	03	04		01	02	03	04
Positiv	53 ²⁾	0	52 ²⁾	53 ²⁾	n.d.	0	0	0	0
Negativ	0	53	1	0	nein no	53	53	53	53
Fraglich Questionable	0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.
Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv True positive results						NAT richtig negativ	
	01		03		04		02	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
Bruker-HAIN GenoType HelicoDR (n = 14)	14	100	14	100	14	100	14	100
CerTest VIASURE H pylori + Clari. (n = 1)	1	100	1	100	1	100	1	100
Ingenetix H. pylori ClariRes (n = 3)	3	100	3	100	3	100	3	100
Seegene Allplex H. pylori + ClariR (n = 12)	12	100	12	100	12	100	12	100
r-Biopharm RIDAGENE H. pylori (n = 7)	7	100	7	100	7	100	7	100
In house PCR assay (n = 12)	12	100	11	92	12	100	12	100
Other commercial tests (n = 4)	4	100	4	100	4	100	4	100

Comments:

1. The following tests are listed under "Other commercial tests": Bioeksen H.pylori/Clarithromycin Resistance qPCR Kit (1x), Sansure Biotech Helicobacter pylori Clarithromycin resistant Diagnostic Kit (1x), FRIZ Biochem (1x) and Savvygen H. pylori and Antibiotic Resistance Kit (1x).
2. Forty-seven of the 53 participants reported results for molecular Clarithromycin-susceptibility testing. Excluding the laboratory with the false negative result, all reported results were correct.